90. Treatment and Prevention of Bone Metastases and Myeloma Bone Disease

  1. Clifford J. Rosen MD
  1. Jean-Jacques Body

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch90

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

Body, J.-J. (2013) Treatment and Prevention of Bone Metastases and Myeloma Bone Disease, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch90

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • bisphosphonates;
  • bone metastases;
  • breast cancer;
  • myeloma bone disease;
  • prostate cancer;
  • tumor bone disease;
  • zoledronic acid

Summary

According to various large series, up to 80-90% of patients with advanced cancer will develop bone metastases. The skeleton is the most common site of metastatic disease. It is also the most frequent site of first distant relapse in breast and prostate cancers. Metastatic bone disease causes considerable distress to breast cancer patients. Due to the long clinical course breast cancer may follow, morbidity due to tumor bone disease also makes major demands on resources for health care provision. Bone pain is a presenting feature in three-fourths of the patients with multiple myeloma. Bisphosphonates were first successfully used in tumor-induced hypercalcemia. Bisphosphonates, especially zoledronic acid, constitute an important part of our therapeutic armamentarium to reduce the skeletal morbidity rate in patients with bone metastases and to preserve bone health in patients with early stage breast cancer.